US equities |
NVDA $234.44 ▲+1.55% MU $1,075.72 ▼-1.97% SPCX $159.13 ▲+7.47% TSLA $371.58 ▲+4.93% SNDK $1,719.35 ▼-3.82% STX $843.66 ▼-10.78% AMD $631.75 ▲+2.60% INTC $120.15 ▲+0.13%
FinancialContent

Articles published by Adagene Inc.

< Previous 1 2 Next >
News headline image
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene to Participate in Three Upcoming Investor Conferences
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene to Participate in Two Upcoming Investor Conferences
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG INCY
News headline image
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene to Participate in Two Upcoming Investor Conferences
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Provides Business Update and 2026 Objectives
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene to Participate in Two Investor Conferences in September
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene announces up to $25 million strategic investment from Sanofi
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene to Present at Jefferies Global Healthcare Conference 2025
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
News headline image
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting
From Adagene Inc.
Via GlobeNewswire
Tickers ADAG
< Previous 1 2 Next >